These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8439634)

  • 1. Review article: S-adenosyl-L-methionine--a new therapeutic agent in liver disease?
    Osman E; Owen JS; Burroughs AK
    Aliment Pharmacol Ther; 1993 Feb; 7(1):21-8. PubMed ID: 8439634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S-adenosyl-L-methionine. A review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism.
    Friedel HA; Goa KL; Benfield P
    Drugs; 1989 Sep; 38(3):389-416. PubMed ID: 2680435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [S-adenosyl-L-methionine (SAMe) and its use in hepatology].
    Frezza M; Terpin MM; Peri A
    Minerva Gastroenterol Dietol; 1992; 38(3):145-51. PubMed ID: 1299337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis.
    Almasio P; Bortolini M; Pagliaro L; Coltorti M
    Drugs; 1990; 40 Suppl 3():111-23. PubMed ID: 2081476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective effect of S-adenosyl-l-methionine on liver damage induced by biliary obstruction in rats: a histological, ultrastructural and biochemical approach.
    Muriel P; Suarez OR; Gonzalez P; Zuñiga L
    J Hepatol; 1994 Jul; 21(1):95-102. PubMed ID: 7963428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S-adenosyl-L-methionine: its role in the treatment of liver disorders.
    Lieber CS
    Am J Clin Nutr; 2002 Nov; 76(5):1183S-7S. PubMed ID: 12418503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis.
    Guo T; Chang L; Xiao Y; Liu Q
    PLoS One; 2015; 10(3):e0122124. PubMed ID: 25774783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms and consequences of the impaired trans-sulphuration pathway in liver disease: Part II. Clinical consequences and potential for pharmacological intervention in cirrhosis.
    Pisi E; Marchesini G
    Drugs; 1990; 40 Suppl 3():65-72. PubMed ID: 2081482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of extrahepatic membrane cholesterol deposition in patients with chronic liver diseases by S-adenosyl-L-methionine.
    Rafique S; Guardascione M; Osman E; Burroughs AK; Owen JS
    Clin Sci (Lond); 1992 Sep; 83(3):353-6. PubMed ID: 1327655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of S-adenosyl-L-methionine on liver damage in experimental obstructive jaundice.
    Tsai SM; Lee KT; Tsai LY
    Kaohsiung J Med Sci; 2001 Sep; 17(9):455-60. PubMed ID: 11842648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility.
    Anstee QM; Day CP
    J Hepatol; 2012 Nov; 57(5):1097-109. PubMed ID: 22659519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease.
    Hardy ML; Coulter I; Morton SC; Favreau J; Venuturupalli S; Chiappelli F; Rossi F; Orshansky G; Jungvig LK; Roth EA; Suttorp MJ; Shekelle P
    Evid Rep Technol Assess (Summ); 2003 Aug; (64):1-3. PubMed ID: 12899148
    [No Abstract]   [Full Text] [Related]  

  • 13. Extrahepatic cell membrane lipid abnormalities and cellular dysfunction in liver disease.
    Owen JS
    Drugs; 1990; 40 Suppl 3():73-83. PubMed ID: 2081483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of S-adenosyl-L-methionine in the treatment of liver diseases.
    Lieber CS
    J Hepatol; 1999 Jun; 30(6):1155-9. PubMed ID: 10406198
    [No Abstract]   [Full Text] [Related]  

  • 15. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results.
    Ribalta J; Reyes H; Gonzalez MC; Iglesias J; Arrese M; Poniachik J; Molina C; Segovia N
    Hepatology; 1991 Jun; 13(6):1084-9. PubMed ID: 2050326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemistry and pharmacology of S-adenosyl-L-methionine and rationale for its use in liver disease.
    Chawla RK; Bonkovsky HL; Galambos JT
    Drugs; 1990; 40 Suppl 3():98-110. PubMed ID: 2081485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S-Adenosyl-L-methionine (SAMe): from the bench to the bedside--molecular basis of a pleiotrophic molecule.
    Bottiglieri T
    Am J Clin Nutr; 2002 Nov; 76(5):1151S-7S. PubMed ID: 12418493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effect of S-adenosyl-L-methionine in hepatic uroporphyria. Evaluation in an experimental model.
    Cantoni L; Budillon G; Cuomo R; Rodinò S; Le Grazie C; Di Padova C; Rizzardini M
    Scand J Gastroenterol; 1990 Oct; 25(10):1034-40. PubMed ID: 2263875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism of exogenous S-adenosyl-L-methionine in patients with liver disease.
    Kaye GL; Blake JC; Burroughs AK
    Drugs; 1990; 40 Suppl 3():124-8. PubMed ID: 2081477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation by S-adenosyl-L-methionine of hepatic Na+,K+-ATPase, membrane fluidity, and bile flow in rats with ethinyl estradiol-induced cholestasis.
    Boelsterli UA; Rakhit G; Balazs T
    Hepatology; 1983; 3(1):12-7. PubMed ID: 6295906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.